Tweet
Ann Pharmacother. 2018 Apr 1:1060028018772579. doi: 10.1177/1060028018772579. [Epub ahead of print]
Providing Additional "Muscle" for Older Adults Through Optimal Influenza Vaccine Selection.
Dougherty JA1, Chahine EB1.
Author information
Abstract
Immunization is the best strategy to protect individuals from influenza; however, older adults tend to respond less favorably to vaccines because of immunosenescence. The Centers for Disease Control and Prevention states that any licensed, recommended, and age-appropriate influenza vaccine may be used in older adults despite reasonable evidence suggesting that the high-dose and, to a lesser extent, the adjuvanted and recombinant influenza vaccines provide better protection than the standard-dose vaccines in this vulnerable population. In this era of precision medicine, clinicians can preferentially recommend these contemporary vaccines to equip their older patients with the best possible protection against influenza.
KEYWORDS:
evidence-based medicine; geriatrics; immunizations; vaccines; viral infections
PMID: 29660994 DOI: 10.1177/1060028018772579
Providing Additional "Muscle" for Older Adults Through Optimal Influenza Vaccine Selection.
Dougherty JA1, Chahine EB1.
Author information
Abstract
Immunization is the best strategy to protect individuals from influenza; however, older adults tend to respond less favorably to vaccines because of immunosenescence. The Centers for Disease Control and Prevention states that any licensed, recommended, and age-appropriate influenza vaccine may be used in older adults despite reasonable evidence suggesting that the high-dose and, to a lesser extent, the adjuvanted and recombinant influenza vaccines provide better protection than the standard-dose vaccines in this vulnerable population. In this era of precision medicine, clinicians can preferentially recommend these contemporary vaccines to equip their older patients with the best possible protection against influenza.
KEYWORDS:
evidence-based medicine; geriatrics; immunizations; vaccines; viral infections
PMID: 29660994 DOI: 10.1177/1060028018772579